Essayer OR - Gratuit
Harnessing data analytics to propel drug discovery and development in 2025
Express Pharma
|December 2024
As the pharma landscape evolves, data analytics will be at the forefront of drug discovery and development, transforming traditional methods. By leveraging data-driven insights, companies can expedite R&D, optimise clinical trials, and personalise treatments, bringing life-saving therapies to market more efficiently, explains Biju Davis, SVP, Engineering, Model N
In 2025, pharmaceutical innovation is in a race against time-each day lost in drug development could mean lives unaltered or unextended. As the demand for quicker, more precise medical solutions intensifies, data analytics has emerged not just as a powerful tool but as a lifeline, reshaping the way we discover, test, and deliver lifesaving treatments. With costs soaring up to $2 billion and development spanning more than a decade, as detailed by a Deloitte 2023 report, the stakes have never been higher, and the role of data-driven insights has never been clearer.
The rising need for data-driven insights in pharma
Globally, healthcare generates approximately 80 per cent of the world's data, with the volume expected to grow at a compound annual growth rate (CAGR) of 36 per cent through 2025. India's biotechnology sector has grown to over $130 billion in 2024 and is projected to reach $300 billion by 2030. The significant growth highlights the immense potential in harnessing data analytics to optimise drug discovery, particularly as clinical trials and R&D investments expand to meet both domestic and global demand. This surge in patient health data, clinical research findings, and real-world evidence presents unprecedented opportunities for breakthroughs, but it also underscores the limitations of traditional methods.
Data analytics solutions, through predictive models and deep learning, enable pharma companies to leverage this wealth of information, offering visibility into emerging health trends, patient outcomes, and clinical success indicators. The insights derived reveal critical details about disease progression, treatment efficacy, and demographic-specific responses, allowing researchers to make well-informed, real-time decisions. Data analytics, thus, has become central to producing the insights necessary to thrive in today's high-stakes pharma landscape.
Cette histoire est tirée de l'édition December 2024 de Express Pharma.
Abonnez-vous à Magzter GOLD pour accéder à des milliers d'histoires premium sélectionnées et à plus de 9 000 magazines et journaux.
Déjà abonné ? Se connecter
PLUS D'HISTOIRES DE Express Pharma
Express Pharma
Standardisation vs customisation in single-use systems for bioprocessing: What do biopharma companies need?
Priyabrata Pattnaik, CEO, Ami Polymer highlights the balance between standardisation and customisation in single - use systems in biopharma manufacturing
5 mins
May 2026
Express Pharma
Ensuring Pharma compliance with testo data measurement technology
Due to the crucial necessity and its direct impact on human health and welfare, Pharma is probably the most important and critical sector among others.
3 mins
May 2026
Express Pharma
China+1 moment for pharma: How India can convert opportunity into long-term contracts
Manish Jain, Director, Naprod Life Sciences explains how India must move beyond cost advantage to lead with reliability, quality, and transparency to reshape global pharma supply chains and position itself as a trusted, long-term partner
3 mins
May 2026
Express Pharma
Beyond scale: Rethinking new frontiers in building excellence
At the Injectable Innovations Conclave 2026, hosted by Express Pharma, industry leaders examined the trends, technologies and strategies shaping the next phase of injectable growth, reports
10 mins
May 2026
Express Pharma
Waters receives CE mark for BD BACTEC FXI Culture System under EU IVDR
Next-generation blood culture system records ~3-hour faster detection time and introduces automated blood volume measurement
2 mins
May 2026
Express Pharma
JNPC: Carrying forward a 20-year old legacy
Billed as India's first bulk drug, chemicals and allied manufacturing parks and one of the most successful public-private partnerships (PPP) in the pharma sector, the Jawaharlal Nehru Pharma City (JNPC), also known as Visakha Pharma City, was set up in February 2005 as a PPP initiative by the Govt of Andhra Pradesh (GoAP) through its nodal agency Andhra Pradesh Industrial Infrastructure Corporation (APIIC) with the Ramky Group on a Build-Own-Operate (BOO) basis for 20 years.
3 mins
May 2026
Express Pharma
Romaco's sustainable blister packaging line at interpack
At this year's interpack, the Romaco Group will present its sustainable Unity 600 high-speed blister packaging line, featuring – for the first time – the PF 75 stretch bander.
6 mins
May 2026
Express Pharma
Even drug-resistant cancer targets can be tackled with the right design strategy
Dr Bajarang Kumbhar, Assistant Professor, Sunandan Divatia School of Science, NMIMS Mumbai, explains how Al-driven computational biology is reshaping CAR-T therapy and highlights how these approaches help cut drug discovery timelines and improve targeted, personalised cancer treatment, in an interaction with Kalyani Sharma
7 mins
May 2026
Express Pharma
Navigating legal and regulatory landscape of GLP-1 drugs in India
GLP-1 drugs are drawing sharp regulatory and legal scrutiny, especially with generics entering post-patent expiry. They emphasise that navigating IP, compliance, and marketing rules is now critical for stakeholders
5 mins
May 2026
Express Pharma
From back office to brain trust: How life sciences GCCs are redefining leadership hiring in India
Sai Gandhi, Partner, Positive Moves points out that life sciences GCCs in India are moving from support roles to driving core innovation and global strategy. In turn, leadership hiring is shifting toward cross-functional, globally savvy leaders who can deliver enterprise-wide impact
4 mins
May 2026
Listen
Translate
Change font size
